Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$3.94 USD
-0.04 (-1.01%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $3.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GLUE 3.94 -0.04(-1.01%)
Will GLUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLUE
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
Other News for GLUE
Monte Rosa Therapeutics GAAP EPS of -$0.43, revenue of $4.7M
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
TD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics: Q2 Earnings Snapshot
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update